On Monday, Shares of Newport Corp (NASDAQ:NEWP), lost -10.47% to $15.99.
Newport Corporation, declared that it presently anticipates its sales for the second quarter of 2015 to be in the range of $147 million to $148 million, contrast with the company’s previous guidance of $154 million to $161 million. In addition, Newport now anticipates its non-GAAP earnings per diluted share for the second quarter of 2015 to be in the range of $0.24 to $0.26, not taking into account the amortization of intangible assets, stock-based compensation expense, acquisition-related, restructuring and severance costs, losses on disposals of assets and the tax impact of the excluded amounts. The lower predictable earnings are due to the lower sales level, a loss of about $1.4 million (or $0.02 per diluted share) from the company’s newly attained Femtolasers business, and an inventory charge of about $1.1 million (or $0.02 per diluted share).
Commenting on the revised outlook, Robert J. Phillippy, Newport’s President and Chief Executive Officer, stated, “We are disappointed in our second quarter performance, and we are implementing specific actions to improve our company’s financial results going forward. Despite the lower second quarter sales, we continue to expect record sales for 2015. In addition, we expect our sales and non-GAAP net income for the second half of 2015 to be higher than our first half results.”
Newport Corporation, together with its auxiliaries, provides technology products and systems for scientific research, microelectronics, defense and security, life and health sciences, and industrial markets worldwide. The company operates in three groups: Photonics, Lasers, and Optics.
Shares of Baytex Energy Corp (USA) (NYSE:BTE), declined -7.06% to $11.06, during its last trading session.
Baytex Energy Corp., reported that a cash dividend of $0.10 per common share in respect of July operations will be paid on August 14, 2015 to shareholders of record on July 23, 2015. The ex-dividend date is July 21, 2015. This dividend is an eligible dividend for the purposes of the Income Tax Act (Canada).
The U.S. dollar equivalent dividend amount is about US$0.0787 per share assuming a foreign exchange rate of $0.7865 USD/CAD. The actual U.S. dollar equivalent dividend for shareholders who hold through a brokerage firm will be based on the exchange rate in effect on the payment date and net of applicable Canadian withholding taxes. Registered shareholders are paid directly by Baytex’s transfer agent, Valiant Trust Company, and the actual U.S. dollar equivalent dividend will be based on the exchange rate in effect on the record date and paid net of applicable Canadian withholding taxes.
Baytex Energy Corp., an oil and gas company, engages in the acquisition, development, exploitation, and production of oil and natural gas in the Western Canadian Sedimentary Basin and the United States.
At the end of Monday’s trade, Shares of Humana Inc (NYSE:HUM), lost -0.68% to $186.16.
As part of its focus on assisting people achieve lifelong well-being, Humana Inc. (HUM), one of the nation’s leading health and well-being companies, has extended its relationship with global well-being improvement leader Healthways (HWAY) to offer the award-winning SilverSneakers Fitness Program through 2020.
SilverSneakers, the nation’s leading exercise and social support program for older adults, is accessible to more than 12 million Medicare beneficiaries. Since 2004, the program has been offered to Humana Medicare Advantage and Medicare Supplement members, a total of more than three million Humana Medicare members nationwide.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.
Finally, CEL-SCI Corporation (NYSEMKT:CVM), ended its last trade with -4.58% gain, and closed at $0.625.
CEL-SCI Corporation, declared it has added a second clinical site for its Phase I clinical trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women with its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection). Dr. Joel Palefsky, world renowned scientist and Key Opinion Leader (KOL) in human papilloma virus (HPV) research and the prevention of anal cancer, has joined the study as a Principal Investigator at the University of California San Francisco (UCSF). UCSF becomes the second clinical site for the study. The first site, the U.S. Naval Medical Center San Diego, continues to enroll patients under a Cooperative Research and Development Agreement (CRADA).
Dr. Joel Palefsky is the Chair of the HPV Working Group of the AIDS Malignancy Consortium (AMC) and is the head of the AMC HPV Virology Core Lab at UCSF. The AMC is a U.S. National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers. The AMC is composed of over 37 clinical trials sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Administration Office. Collectively, these components develop and oversee the scientific agenda, manage the groups’ portfolio of clinical trials and other scientific-based studies, and assist to develop new protocols. Dr. Palefsky has extensive experience in the biology of HPV infection, HPV infection in HIV-positive men and women, HPV vaccines and in the design and implementation of multiple clinical research trials of HPV-related disease.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
